COVID ‐19 Vaccine Response in People with Multiple Sclerosis

Emma Tallantyre; Nicola Vickaryous; Valerie Anderson; Aliye Nazli Asardag; David Baker; Jonathan P. Bestwick; Kath Bramhall; Randy Chance; Nikos Evangelou; Katila George; Gavin Giovannoni; Andrew Godkin; Leanne Grant; Katharine Harding; Aimee Hibbert; Gillian Ingram; Meleri Jones; Angray S. Kang; Samantha Loveless; Stuart J. Moat; Neil P. Robertson; Klaus Schmierer; Martin Scurr; Sita Shah; J. Alan Simmons; Matthew Upcott; Mark Willis; Stephen Jolles; Ruth Dobson

doi:10.1002/ana.26251

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Some disease modifying therapies convey risk of attenuated serological response to SARS-CoV-2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a-n/a.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tallantyre et al. (2021) studied this question.

synapsesocial.com/papers/69dd5a248557d5ab8f40d1f7 https://doi.org/10.1002/ana.26251

View Full Paper

Ask AI

Bookmark

Share

COVID ‐19 Vaccine Response in People with Multiple Sclerosis

Ask about this paper

Abstract

Discussion

Cite This Study

COVID ‐19 Vaccine Response in People with Multiple Sclerosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading